The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Liver-Unrelated Comorbid Conditions Do Not Affect Cognitive Performance or Hepatic Encephalopathy Progression in Cirrhosis
Am J Gastroenterol. 2021 Jun 18. doi: 10.14309/ajg.0000000000001346. Online ahead of print.
Chathur Acharya1, Omar Nadhem1, Jawaid Shaw1, Ramzi Hassouneh1, Andrew Fagan1, Sara McGeorge1, Richard K Sterling1, Puneet Puri1, Michael Fuchs1, Velimir Luketic1, Arun J Sanyal1, James B Wade2, HoChong S Gilles3, Douglas M Heuman1, Felicia Tinsley1, Scott Matherly1, Hannah Lee1, Mohammad S Siddiqui1, Leroy R Thacker3, Jasmohan S Bajaj1
Author information
1Department of Gastroenterology Hepatology and Nutrition, VCU Medical Center and Central Virginia VA Healthcare System, Richmond, Virginia, USA.
2Department of Psychiatry, VCU, Richmond, Virginia, USA.
3Department of Biostatistics, VCU, Richmond, Virginia, USA.
Abstract
Introduction: We aimed to determine the effect of comorbidities on covert hepatic encephalopathy (CHE) diagnosis and overt hepatic encephalopathy (OHE) development.
Methods: Cirrhotic outpatients underwent CHE testing and 2-year follow-up. Cox regression was performed for time to OHE. In total, 700 patients (60 years, 84% men, model for end-stage liver disease 11) and 33% prior OHE underwent testing and follow-up.
Results: Major comorbidities were hypertension (54%), diabetes (35%), and depression (29%). Common medications were proton pump inhibitor (49%), beta-blockers (32%), and opioids (21%). Approximately 90 (40%) prior-OHE patients developed recurrence 93 (30,206) days post-testing predicted only by liverrelated variables.
Discussion: Demographics, cirrhosis characteristics, and opioid use, but not other comorbid conditions, were associated with CHE diagnosis and OHE progression.
Stay Informed!
